Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral
sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week …

Background In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS),
edaravone did not show a significant difference in the Revised ALS Functional Rating Scale …

Abstract Background In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients
experienced significantly less physical functional decline with 24‐week edaravone vs …

Background Based on the results of randomized, double-blind, placebo-controlled trials, the
benefit and safety of edaravone in the treatment of amyotrophic lateral sclerosis remain …

The etiology of amyotrophic lateral sclerosis (ALS) is unknown. Oxidative stress may be one
of the major mechanisms involved. In vitro and in vivo data of edaravone suggest that it may …

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, neurodegenerative
disease. Although the pathogenesis remains unresolved, oxidative stress is known to play a …

Importance Intravenous edaravone is approved as a disease-modifying drug for patients
with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term …

Objectives The aim of the study is to analyze the ALS disease progression and respiratory
function of Italian patients treated with edaravone (EVN), as well as the adherence to, and …

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive
and fatal neurodegenerative disease that leads to a loss of muscle control due to nerve cells …

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive fatal disorder that affects all
skeletal muscles, leading to death, mostly within 2–4 years from onset. To date, the anti …